CO6280419A2 - 5-[(3,3,3-trifluoro-2-hidroxi-1-arilpropil)amino]-1h-quinolin-2-onas un proceso para su produccion y uso como agentes inflamatorios - Google Patents

5-[(3,3,3-trifluoro-2-hidroxi-1-arilpropil)amino]-1h-quinolin-2-onas un proceso para su produccion y uso como agentes inflamatorios

Info

Publication number
CO6280419A2
CO6280419A2 CO10061149A CO10061149A CO6280419A2 CO 6280419 A2 CO6280419 A2 CO 6280419A2 CO 10061149 A CO10061149 A CO 10061149A CO 10061149 A CO10061149 A CO 10061149A CO 6280419 A2 CO6280419 A2 CO 6280419A2
Authority
CO
Colombia
Prior art keywords
group
alkyl
nr6r7
optionally substituted
production
Prior art date
Application number
CO10061149A
Other languages
English (en)
Inventor
Markus Berger
Hartmut Rehwinkel
Thomas Zollner
Ekkerhard May
Jorma Hassfeld
Heike Schacke
Original Assignee
Bayer Schering Pharma Ag
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39575536&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6280419(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag, Astrazeneca Ab filed Critical Bayer Schering Pharma Ag
Publication of CO6280419A2 publication Critical patent/CO6280419A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/08Antiseborrheics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/56Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds
    • C07C45/57Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds with oxygen as the only heteroatom
    • C07C45/58Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds with oxygen as the only heteroatom in three-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/70Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
    • C07C45/71Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/82Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/84Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D303/00Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02Compounds containing oxirane rings
    • C07D303/12Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/32Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by aldehydo- or ketonic radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a compuestos de fórmula I, a procesos para su producción y a su uso como agentes antiinflamatorios.1.- Compuestos que responden a la fórmula general 1R1 y R2 significan en forma independiente entre sí un átomo de hidrógeno, un grupo hidroxi, un átomo de halógeno, un grupo (C1-C10)-alquilo opcionalmente sustituido, un grupo (C1-C10)-alcoxi opcionalmente sustituido, un grupo (C1-C10)-alquiltio, un grupo (C1-C5)-perfluoroalquilo, un grupo ciano, un grupo nitro, o R1 y R2 juntos significan un grupo que se selecciona entre los grupos -O-(CH2)p-O-, -O-(CH2)p-(CH2)-, -O-CH=CH-, -(CH2)p+2-, -NH-(CH2)p+1, -N(C1-C3-alquil) - (CH2)p+1, y -NH-N=CH-, donde p = 1 o 2, y los átomos de oxígeno y/o átomos de carbono y/o átomos de nitrógeno terminales están unidos a átomos de carbono del anillo directamente adyacente, o NR6R7, donde R6 y R7, significan en forma independiente entre sí hidrógeno, C1-C5 alquilo o (CO) - (C1-C5) -alquilo, R3 significa un átomo de hidrógeno, un grupo hidroxi, un átomo de halógeno, un grupo ciano, un grupo (C1-C10)-alquilo opcionalmente sustituido, un grupo (C1-C10)-alcoxi, un grupo (C1-C10)-alquiltio, o un grupo (C1-C5)-perfluoroalquilo, R4 significa hidrógeno, halógeno, hidroxi, (C1-C5)-alquilo, (C1-C5)alcoxi, (C1-C5)-alquiltio, (C1-C5)-perfluoroalquilo, ciano, nitro, NR6R7, COOR9, (CO)NR6R7 o un grupo (C1-C5-alquilen)-O-(CO)-(C1-C5) alquilo ...
CO10061149A 2007-11-22 2010-05-21 5-[(3,3,3-trifluoro-2-hidroxi-1-arilpropil)amino]-1h-quinolin-2-onas un proceso para su produccion y uso como agentes inflamatorios CO6280419A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07076019A EP2062880A1 (en) 2007-11-22 2007-11-22 5-[(3,3,3-Trifluoro-2-hydroxy-1-arylpropyl)amino]-1H-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents

Publications (1)

Publication Number Publication Date
CO6280419A2 true CO6280419A2 (es) 2011-05-20

Family

ID=39575536

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10061149A CO6280419A2 (es) 2007-11-22 2010-05-21 5-[(3,3,3-trifluoro-2-hidroxi-1-arilpropil)amino]-1h-quinolin-2-onas un proceso para su produccion y uso como agentes inflamatorios

Country Status (40)

Country Link
US (3) US8394958B2 (es)
EP (2) EP2062880A1 (es)
JP (1) JP5559058B2 (es)
KR (1) KR101580700B1 (es)
CN (2) CN103396300A (es)
AR (1) AR069400A1 (es)
AU (1) AU2008328307C1 (es)
BR (1) BRPI0819833B1 (es)
CA (1) CA2705410C (es)
CL (1) CL2008003472A1 (es)
CO (1) CO6280419A2 (es)
CR (1) CR11452A (es)
CU (1) CU23889B1 (es)
CY (1) CY1118173T1 (es)
DK (1) DK2234979T3 (es)
DO (1) DOP2010000152A (es)
EA (1) EA017459B1 (es)
EC (1) ECSP10010192A (es)
ES (1) ES2588170T3 (es)
HK (1) HK1144817A1 (es)
HN (1) HN2010001060A (es)
HR (1) HRP20161015T1 (es)
HU (1) HUE028865T2 (es)
IL (1) IL205117A (es)
LT (1) LT2234979T (es)
MA (1) MA31834B1 (es)
MX (1) MX2010005528A (es)
MY (1) MY151017A (es)
NZ (1) NZ585495A (es)
PA (1) PA8804601A1 (es)
PE (1) PE20091066A1 (es)
PL (1) PL2234979T3 (es)
PT (1) PT2234979T (es)
RS (1) RS55012B1 (es)
SI (1) SI2234979T1 (es)
TN (1) TN2010000219A1 (es)
TW (1) TWI520736B (es)
UA (1) UA100251C2 (es)
UY (1) UY31479A1 (es)
WO (1) WO2009065503A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1878717A1 (en) 2006-07-14 2008-01-16 Bayer Schering Pharma Aktiengesellschaft Benzyl amines, a process for their production and their use as anti-inflammatory agents
WO2009151569A2 (en) * 2008-06-09 2009-12-17 Combinatorx, Incorporated Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders
US20100016338A1 (en) * 2008-07-21 2010-01-21 Bayer Schering Pharma Aktiengesellschaft 5-[(3,3,3-Trifluoro-2-hydroxy-1-arylpropyl)amino]-1-arylquinolin-2-ones, a Process for their Production and their Use as Anti-inflammatory Agents
JP6061373B2 (ja) * 2012-07-24 2017-01-18 国立研究開発法人産業技術総合研究所 2−ヒドロキシベンズアルデヒド化合物、これを含有するコラーゲン細胞外分泌阻害剤及び医薬品組成物
WO2017025371A1 (en) * 2015-08-07 2017-02-16 Bayer Pharma Aktiengesellschaft Process for the preparation of 5-amino-quinolin-2(1h)-ones and their tautomer forms 5-amino-quinolin-2-ols
WO2017081044A1 (en) 2015-11-13 2017-05-18 Bayer Pharma Aktiengesellschaft 4-(4-cyano-2-thioaryl)dihydropyrimidinones for treating chronic wounds
WO2017161518A1 (en) 2016-03-23 2017-09-28 Astrazeneca Ab New physical form
WO2018046684A1 (en) 2016-09-08 2018-03-15 Bayer Pharma Aktiengesellschaft Process for the preparation of substituted 5-{[2-(alkoxymethyl)-3,3,3-trifluoro-2-hydroxy-1-phenylpropyl]amino}quinolin-2(1h)-ones
WO2018046681A1 (en) 2016-09-08 2018-03-15 Bayer Pharma Aktiengesellschaft Forms of 5-{[(1s,2s)-1-(2-chloro-3-fluoro-4-methoxyphenyl)-3,3,3-trifluoro-2-hydroxy-2-(methoxymethyl)propyl]amino}-7-fluoro-1h-quinolin-2-one
WO2018046678A1 (de) 2016-09-08 2018-03-15 Bayer Aktiengesellschaft Glukokorticoid-rezeptor-agonisten enthaltende formulierungen
WO2018046685A1 (en) 2016-09-08 2018-03-15 Bayer Aktiengesellschaft Quinoline derivatives for treatment of inflammatory skin diseases
AU2020211303A1 (en) * 2019-01-22 2021-07-15 Akribes Biomedical Gmbh Selective Glucocorticoid Receptor Modifiers for treating impaired skin wound healing

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1045180A (en) * 1963-09-20 1966-10-12 Parke Davis & Co Quinazoline derivatives
US4197209A (en) * 1977-03-10 1980-04-08 Ciba-Geigy Corporation Lubricant compositions containing sulfur-containing esters of phosphoric acid
JPH06172321A (ja) 1992-10-08 1994-06-21 Agro Kanesho Co Ltd 置換アミノピリミジン誘導体、その製造法及びそれを有効成分とする有害生物駆除剤
UA57002C2 (uk) * 1995-10-13 2003-06-16 Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування
AU5682299A (en) 1998-08-21 2000-03-14 Scripps Research Institute, The Catalytic asymmetric aminohydroxylation with amino-substituted heterocycles
DE10038639A1 (de) 2000-07-28 2002-02-21 Schering Ag Nichtsteroidale Entzündungshemmer
ES2270955T3 (es) 2000-12-22 2007-04-16 Smithkline Beecham Plc Sal mesilato de 5-(4-(2-(n-metil-n-(2-piridil)amino)etoxi)bencil)tiazolidina-2,4-diona.
EP1490317A1 (en) * 2002-03-26 2004-12-29 Boehringer Ingelheim Pharmaceuticals Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US20050090559A1 (en) * 2003-07-01 2005-04-28 Markus Berger Heterocyclically-substituted pentanol derivatives, process for their production and their use as anti-inflammatory agents
EA200600148A1 (ru) 2003-07-01 2006-08-25 Шеринг Акциенгезельшафт Гетероциклически замещённые производные пентанола, способ их получения и их применение в качестве ингибиторов воспаления
US20050009109A1 (en) * 2003-07-08 2005-01-13 Stanford University Fluorophore compounds and their use in biological systems
DE10347385A1 (de) 2003-10-08 2005-05-12 Schering Ag Umgelagerte Pentanole, ein Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
EP1878717A1 (en) * 2006-07-14 2008-01-16 Bayer Schering Pharma Aktiengesellschaft Benzyl amines, a process for their production and their use as anti-inflammatory agents
US20100016338A1 (en) * 2008-07-21 2010-01-21 Bayer Schering Pharma Aktiengesellschaft 5-[(3,3,3-Trifluoro-2-hydroxy-1-arylpropyl)amino]-1-arylquinolin-2-ones, a Process for their Production and their Use as Anti-inflammatory Agents

Also Published As

Publication number Publication date
PA8804601A1 (es) 2009-06-23
DOP2010000152A (es) 2010-08-15
IL205117A0 (en) 2010-11-30
NZ585495A (en) 2011-05-27
DK2234979T3 (en) 2016-09-05
CU23889B1 (es) 2013-04-19
EA201000814A1 (ru) 2010-12-30
AR069400A1 (es) 2010-01-20
TW200927112A (en) 2009-07-01
BRPI0819833A2 (pt) 2015-05-26
AU2008328307C1 (en) 2013-10-24
EP2234979B1 (en) 2016-05-25
HN2010001060A (es) 2012-11-12
UA100251C2 (uk) 2012-12-10
UY31479A1 (es) 2009-07-17
HRP20161015T1 (hr) 2016-11-18
SI2234979T1 (sl) 2016-12-30
EP2234979A1 (en) 2010-10-06
ECSP10010192A (es) 2010-07-30
MA31834B1 (fr) 2010-11-01
EA017459B1 (ru) 2012-12-28
JP2011504472A (ja) 2011-02-10
WO2009065503A1 (en) 2009-05-28
RS55012B1 (sr) 2016-11-30
US20130005766A1 (en) 2013-01-03
US20090137564A1 (en) 2009-05-28
TWI520736B (zh) 2016-02-11
CY1118173T1 (el) 2017-06-28
ES2588170T3 (es) 2016-10-31
CA2705410C (en) 2016-04-12
JP5559058B2 (ja) 2014-07-23
PL2234979T3 (pl) 2016-11-30
MX2010005528A (es) 2010-06-02
HUE028865T2 (en) 2017-01-30
CL2008003472A1 (es) 2009-11-20
AU2008328307A1 (en) 2009-05-28
MY151017A (en) 2014-03-31
HK1144817A1 (es) 2011-03-11
CN103396300A (zh) 2013-11-20
KR101580700B1 (ko) 2015-12-28
PE20091066A1 (es) 2009-08-27
IL205117A (en) 2015-05-31
KR20100092936A (ko) 2010-08-23
TN2010000219A1 (en) 2011-11-11
USRE47047E1 (en) 2018-09-18
CA2705410A1 (en) 2009-05-28
CU20100099A7 (es) 2011-10-14
AU2008328307B2 (en) 2013-03-28
EP2062880A1 (en) 2009-05-27
PT2234979T (pt) 2016-08-29
CN101868448B (zh) 2013-06-12
BRPI0819833B1 (pt) 2018-11-27
US8394958B2 (en) 2013-03-12
US8680117B2 (en) 2014-03-25
CN101868448A (zh) 2010-10-20
CR11452A (es) 2010-07-15
LT2234979T (lt) 2016-11-10

Similar Documents

Publication Publication Date Title
CO6280419A2 (es) 5-[(3,3,3-trifluoro-2-hidroxi-1-arilpropil)amino]-1h-quinolin-2-onas un proceso para su produccion y uso como agentes inflamatorios
CO6150135A2 (es) Bencilaminas un proceso para su produccion y su uso como agentes antiinflamatorios
ES2568009T3 (es) Procedimiento para la absorción de CO2 a partir de una mezcla gaseosa con un medio de absorción que contiene aminas
AR070479A1 (es) Derivado heterociclico fusionado y su uso
UY29742A1 (es) Procedimiento para la preparación de betamimeticos
CO6210751A2 (es) Derivados de indolinona y procedimiento para su fabricacion
BRPI0915692B8 (pt) compostos derivados de 1,2,5-oxadiazóis, sua forma sólida, sua composição, bem como seus usos
ECSP10010271A (es) Derivados de tiazol usados como inhibidores de pi 3-cinasa
DOP2010000047A (es) Compuestos de pirazol y su uso como inhibidores de raf
DOP2011000237A (es) Inhibidores de poli (adp-ribosa) polimerasa (parp)
ECSP078060A (es) 2,4-diamino-pirimidinas como inhibidores de aurora
CR20140091A (es) Nuevos derivados dihidroquinolina-2-ona
DOP2011000217A (es) Nuevas bencenosulfonamidas como bloqueadores de canales de calcio
BRPI0812222A2 (pt) Compostos ciclobutenodiona substituídos anti-inflamatórios.
ECSP11011244A (es) Nuevos herbicidas.
PA8779101A1 (es) "compuestos tricíclicos como inhibidores de metaloproteinasas matriciales"
CR10671A (es) Compuestos azabiciclicos como inhibidores de la recaptacion de monoaminas
UY32395A (es) Compuesto con anillo fusionado y su uso
CO6362013A2 (es) Derivados de rifamicina
UY32635A (es) Derivados de bis-(sulfonilamino) en terapia 735
CL2023003154A1 (es) Compuestos heterocíclicos
CO6290665A2 (es) Derivados de oxindol sustituido y su uso para el tratamiento de enfermedades dependientes de la vasopresina
AR070874A1 (es) Compuesto heterociclico fusionado, una composicion farmaceutica que lo comprende y su uso en el tratamiento del cancer.
UY33179A (es) Derivados de ácido carboxílico que comprenden un anillo de oxazolopirimidina 2,5-sustituido.
EA201200150A1 (ru) Новые гербициды

Legal Events

Date Code Title Description
FG Application granted